TD Asset Management Inc. Decreases Stake in Danaher Co. (NYSE:DHR)

TD Asset Management Inc. reduced its stake in shares of Danaher Co. (NYSE:DHRGet Rating) by 6.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,359,230 shares of the conglomerate’s stock after selling 92,007 shares during the period. TD Asset Management Inc.’s holdings in Danaher were worth $398,703,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in DHR. US Asset Management LLC boosted its position in shares of Danaher by 0.6% in the 1st quarter. US Asset Management LLC now owns 5,774 shares of the conglomerate’s stock worth $1,694,000 after buying an additional 37 shares in the last quarter. Mairs & Power Inc. boosted its position in shares of Danaher by 4.1% in the 4th quarter. Mairs & Power Inc. now owns 959 shares of the conglomerate’s stock worth $316,000 after buying an additional 38 shares in the last quarter. Mutual Advisors LLC boosted its position in shares of Danaher by 0.7% in the 4th quarter. Mutual Advisors LLC now owns 5,792 shares of the conglomerate’s stock worth $1,906,000 after buying an additional 40 shares in the last quarter. Duff & Phelps Investment Management Co. raised its stake in Danaher by 0.6% in the 4th quarter. Duff & Phelps Investment Management Co. now owns 6,727 shares of the conglomerate’s stock valued at $2,213,000 after purchasing an additional 41 shares during the last quarter. Finally, Encompass Wealth Advisors LLC raised its stake in Danaher by 1.9% in the 1st quarter. Encompass Wealth Advisors LLC now owns 2,292 shares of the conglomerate’s stock valued at $672,000 after purchasing an additional 42 shares during the last quarter. 78.42% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Danaher news, EVP Joakim Weidemanis sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $271.13, for a total value of $3,253,560.00. Following the completion of the transaction, the executive vice president now owns 74,398 shares in the company, valued at approximately $20,171,529.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Joakim Weidemanis sold 12,000 shares of the stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $271.13, for a total transaction of $3,253,560.00. Following the completion of the transaction, the executive vice president now directly owns 74,398 shares in the company, valued at approximately $20,171,529.74. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Walter G. Lohr sold 3,906 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $273.84, for a total value of $1,069,619.04. Following the sale, the director now directly owns 12,115 shares in the company, valued at $3,317,571.60. The disclosure for this sale can be found here. 11.20% of the stock is owned by company insiders.

Danaher Stock Down 1.1 %

NYSE DHR traded down $3.42 on Wednesday, reaching $297.06. The company had a trading volume of 59,453 shares, compared to its average volume of 2,118,268. The firm has a market capitalization of $216.10 billion, a PE ratio of 35.02, a P/E/G ratio of 2.42 and a beta of 0.86. Danaher Co. has a 1 year low of $233.71 and a 1 year high of $333.96. The firm has a 50-day moving average of $265.83 and a 200-day moving average of $269.07. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.75 and a quick ratio of 1.32.

Danaher (NYSE:DHRGet Rating) last released its quarterly earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, topping analysts’ consensus estimates of $2.35 by $0.41. The firm had revenue of $7.75 billion during the quarter, compared to analysts’ expectations of $7.29 billion. Danaher had a return on equity of 18.57% and a net margin of 20.61%. Danaher’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.46 EPS. On average, equities research analysts anticipate that Danaher Co. will post 10.4 EPS for the current fiscal year.

Analyst Ratings Changes

DHR has been the subject of several analyst reports. William Blair reissued an “outperform” rating on shares of Danaher in a research note on Friday, April 22nd. UBS Group boosted their target price on shares of Danaher from $297.00 to $323.00 and gave the company a “buy” rating in a research note on Thursday, July 28th. Wells Fargo & Company downgraded shares of Danaher from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $330.00 to $265.00 in a research note on Monday, April 25th. KeyCorp cut their target price on shares of Danaher from $345.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday, July 22nd. Finally, Evercore ISI dropped their price objective on shares of Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a research note on Tuesday, July 5th. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Danaher has an average rating of “Buy” and an average target price of $326.50.

Danaher Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

See Also

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.